Anticancer agent 333
Anticancer agent 333 is a tetrazinone anticancer agent with broad-spectrum anticancer activity, targeting MGMT/AGT-deficient cancer cells (IC50≤20 μM). Anticancer agent 333 exhibits favorable safety profiles in rat and canine animal models. Anticancer agent 333 can be used for the research of MGMT-deficient cancers and related tumors.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3075414-82-0
- Fòrmula: C8H7F3N6O3
- Peso molecular:292.17
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas DNA Methyltransferase
More
Actividad biológica
|
MGMT |
Anticancer agent 333 (I-1) weakly inhibits viability of MGMT positive / MMR positive and MGMT positive / MMR negative LN229 glioblastoma cells, with an IC50 greater than 100 μM for both cell lines[1].
Anticancer agent 333 (I-1) exhibits broad anti-cancer activity across diverse human cancer cell lines, with the highest potency (EC50/IC50 ≤ 30 μM) in most lymphoma, small cell lung carcinoma, colon carcinoma, melanoma, and glioblastoma cell lines tested[1].
Anticancer agent 333 (I-1) (66.7 μM; 5 days) exhibits lineage-dependent anti-cancer activity across 885 human cancer cell lines, with the most potent effects (Log2 fold change -3.5 to -2.0) observed in a subset of tested cell lines when treated at 66.7 μM for 5 days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:885 barcoded human cancer cell lines across over 45 lineages
-
Concentration:66.7 μM; 8-point 3-fold dilution dose range
-
Incubation Time:5 days
-
Result:Caused log2 fold change -3.5 to -2.0 (highly significant anti-cancer effect) in a subset of cell lines.
Caused log2 fold change >-2.0 to -1.0 (significant anti-cancer effect) in a subset of cell lines.
Caused log2 fold change >-1.0 to -0.5 (moderate anti-cancer effect) in a subset of cell lines including KYSE510, LS180, HOS, ASPC1, and others.
Caused log2 fold change >-0.5 to -0.001 (weak anti-cancer effect) in a subset of cell lines including RD, NCI-H1563, MONOMAC6, and others.
Showed no detectable anti-cancer effect in a subset of cell lines.
Chemical Information
-
No. CAS 3075414-82-0
-
Peso molecular 292.17
-
Fòrmula C8H7F3N6O3
-
SMILES
O=C(C(N=CN12)=C2N=NN(CCOC(F)(F)F)C1=O)N
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 333 Related Classifications
HY-186228 Related Classifications
Powered by Bioz
- Anticancer agent 333
- 3075414-82-0
- Anticancer agent333
- Anticancer agent-333
- DNA Methyltransferase
- dogs
- MGMT-deficient cancer cells
- MGMT-negative/MMR-negative glioblastoma cells
- colon cancer
- MGMT-proficient cancer cells
- lung cancer
- rats
- head and neck squamous cell carcinoma
- glioma
- MGMT-negative/MMR-positive glioblastoma cells
- Inhibitor
- inhibitor
- inhibit